
    
      Study will evaluate the efficacy of a new compound versus placebo in the treatment of
      patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from
      baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from
      the Positive and Negative Syndrome Scale (PANSS).
    
  